2.

患者的无进展生存及总生存Kaplan-Meier生存曲线。A:所有患者中EGFR外显子19缺失对比外显子21点突变的PFS生存曲线; B:口服Gefi组对比Erlo组的PFS生存曲线; C:男性患者中口服Gefi组对比Erlo组的PFS生存曲线; D:女性患者中口服Gefi组对比Erlo组的PFS生存曲线; E:吸烟患者中口服Gefi组对比Erlo组的PFS生存曲线; F:不吸烟患者中口服Gefi组对比Erlo组的PFS生存曲线。

Kaplan-Meier curves of PFS and OS.A:PFS comparing between exon 19 mutation and exon 21 mutation in all patients; B:PFS comparing between gefitinib and erlotinib; C:PFS comparing between gefitinib and erlotinib in male patients; D:PFS comparing between gefitinib and erlotinib in female patients; E:PFS comparing between gefitinib and erlotinib in smoking patients; F:PFS comparing between gefitinib and erlotinib in non-smoking patients.PFS:progression free survival.